Randomized multicenter phase II study of larotaxel (XRP9881) in combination with cisplatin or gemcitabine as first-line chemotherapy in nonirradiable stage IIIB or stage IV non-small cell lung cancer

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F08%3A00001278" target="_blank" >RIV/00216208:11120/08:00001278 - isvavai.cz</a>

Alternative codes found

RIV/00064211:_____/08:#0000026

Result on the web

—

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Randomized multicenter phase II study of larotaxel (XRP9881) in combination with cisplatin or gemcitabine as first-line chemotherapy in nonirradiable stage IIIB or stage IV non-small cell lung cancer

Original language description

INTRODUCTION: This randomized phase II study investigated the efficacy and safety of a new taxane, larotaxel (XRP9881), in combination with either cisplatin or gemcitabine in the first-line treatment of patients with nonirradiable stage IIIB or stage IVnon-small cell lung cancer to select the combination having the most promising antitumor activity. METHODS: Patients received either larotaxel (50 mg/m) as a 1-hour infusion, followed by a 1-hour infusion of cisplatin (75 mg/m), every 3 weeks (arm A), orgemcitabine (800 mg/m) as a 30 minute infusion, on days 1 and 8, and larotaxel (60 mg/m) as a 1-hour infusion, on day 8 (following gemcitabine), every 3 weeks (arm B). The primary end point was the objective response rate (per-protocol population). RESULTS: Thirty-two patients were randomized to arm A and 30 to arm B. The response rate was higher in arm A compared with arm B in both the per-protocol (26.7% versus 18.2%) and intention-to-treat (28.1% versus 13.3%) populations. In the int

Czech name

Randomizovaná multicentrická studie fáze II s larotaxelem (XRP9881) v kombinaci s cisplatinou nebo gemcitabinem v první linii chemoterapie nemalobuněčného karcinomu plic stadia IIIB nebo IV, kteří nejsou indikováni k radioterapii

Czech description

Randomizovaná multicentrická studie fáze II s larotaxelem (XRP9881) v kombinaci s cisplatinou nebo gemcitabinem v první linii chemoterapie nemalobuněčného karcinomu plic stadia IIIB nebo IV, kteří nejsou indikováni k radioterapii

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FC - Pneumology

OECD FORD branch

—

Project

—

Continuities

Z - Vyzkumny zamer (s odkazem do CEZ)

Publication year

2008

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Journal of Thoracic Oncology

ISSN

1556-0864

e-ISSN

—

Volume of the periodical

3

Issue of the periodical within the volume

8

Country of publishing house

US - UNITED STATES

Number of pages

8

Pages from-to

—

UT code for WoS article

000258447300013

EID of the result in the Scopus database

—